ThinkEquity upgraded shares of Radiopharm Theranostics Limited – American Depositary Shares (NASDAQ:RADX – Free Report) to a strong-buy rating in a report published on Monday,Zacks.com reports.
Separately, Maxim Group began coverage on Radiopharm Theranostics Limited – American Depositary Shares in a report on Thursday, May 1st. They issued a “buy” rating and a $12.00 target price for the company.
Get Our Latest Research Report on Radiopharm Theranostics Limited – American Depositary Shares
Radiopharm Theranostics Limited – American Depositary Shares Stock Performance
About Radiopharm Theranostics Limited – American Depositary Shares
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Featured Articles
- Five stocks we like better than Radiopharm Theranostics Limited – American Depositary Shares
- About the Markup Calculator
- 2 High Growth Buy Now, Pay Later Stocks Challenging PayPal
- Top Biotech Stocks: Exploring Innovation Opportunities
- Analysts Say Unilever Has the Leverage to Hit New Highs
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Homebuilders: Oversold, Undervalued, and Ready to Run?
Receive News & Ratings for Radiopharm Theranostics Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
